PRKAA1 and cancer: This newly identified AMPK/Skp2/Akt pathway provides not only the molecular basis of how AMPK serves a protective and survival advantage under diverse stresses, but also offers a novel therapeutic strategy for cancer treatment and overcoming acquired resistance to EGFR targeted therapy.